Allergic Bronchopulmonary Aspergillosis Panel II
ABPA is a hypersensitivity disease of the lungs caused by Aspergillus fumigatus. It is an important complication for patients with asthma and cystic fibrosis. Diagnosis involves clinical, immunologic and radiographic criteria and no single test is sufficiently discriminating. ABPA is under-diagnosed: prospective studies indicate that 7 to 14 % of patients with corticosteroid-dependent asthma meet the generally accepted definitions as to 6% of patients with cystic fibrosis. Individuals with the HLA DR2 and HLA DR5 haplotypes appear to be predisposed to ABPA.
see individual test information
3-5 business days from receipt of specimen
|Specimen Type||Order Code||CPT Code||NY Approved||Volume||Assay Range||Special Instructions|
|serum||403016P||(82785 x 1), (86001 x 1), (86003 x 1), (86331 x 1)||No||
See Individual Test
Specimens are approved for testing in New York only when indicated in the Specimen Information field above.
The CPT codes provided are based on Viracor Eurofins' interpretation of the American Medical Association's Current Procedural Terminology (CPT) codes and are provided for general informational purposes only. CPT coding is the sole responsibility of the billing party. Questions regarding coding should be addressed to your local Medicare carrier. Viracor Eurofins assumes no responsibility for billing errors due to reliance on the CPT codes illustrated in this material.